A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent of GISTS.

Crenolanib is an investigational new drug being developed by AROG Pharmaceuticals. Crenolanib is a tyrosine kinase inhibitor that acts by inhibiting PDGFRA and PDGFRB.

The study was done by Michael C. Heinrich and colleagues and was titled “Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors.”

Based in part on these results, a phase II clinical study has been initiated.

LRG Contributor
Author: LRG Contributor